Abstract
Purpose :
Triamcinolone acetonide injectable suspension for suprachoroidal use (SCS-TA) provides targeted steroid delivery to the choroid/retina while minimizing exposure in nontarget tissues. The PEACHTREE Study evaluated SCS-TA for macular edema (ME) secondary to noninfectious uveitis (NIU). In these post-hoc analyses, we evaluated the efficacy and safety of SCS-TA in subjects from PEACHTREE categorized by discreet anatomic subtype of uveitis.
Methods :
In PEACHTREE, 160 NIU subjects with ME were randomized 3:2 to SCS-TA or sham procedure at baseline and week 12 and were followed for 24 weeks. Subjects diagnosed with NIU of any anatomic subtype, including anterior-, intermediate-, posterior-, and pan-uveitis, were included. Herein, efficacy endpoints, including changes in best corrected visual acuity (BCVA), central subfield retinal thickness (CST), and safety endpoints, including adverse event (AE) reports and intraocular pressure (IOP), were evaluated in subjects diagnosed with NIU in a single anatomic location.
Results :
Of subjects in the SCS-TA and control arm, 13 vs 7 had anterior uveitis, 21 vs 15 had intermediate uveitis, 20 vs 11 had posterior uveitis, and 30 vs 24 had panuveitis. Across NIU subtypes, at week 24, SCS-TA-treated subjects showed significant improvements from baseline in BCVA ranging from 12.1 to 15.9 letters, while control subjects showed changes ranging from -1.6 to 9.1 letters, with significant between-treatment differences among subjects diagnosed with posterior- or pan-uveitis (P≤0.024). Similarly, changes in CST ranging from -120.1 to -189.0 µm were observed in SCS-TA-treated subjects vs -20.3 to 10.2 µm in control subjects, with significant between-treatment differences among intermediate-, posterior- and pan-uveitis subtypes (P≤0.014). Reports of AEs appeared similar between treatments by anatomic subtype. At week 24, SCS-TA-treated subjects showed IOP changes of 0.5 to 3.1 mm Hg compared to -1.2 to 1.7 mm Hg in control subjects.
Conclusions :
Treatment with SCS-TA resulted in significant BCVA improvements from baseline in all anatomic NIU subtypes and was significantly better vs control in posterior- and pan-uveitis. Significant improvements in CST from baseline were observed vs both baseline and control for most anatomic NIU locations. Safety findings were comparable across discreet NIU subtypes.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.